How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,334 results for

Aphasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3721. Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease

Sponsors and Collaborators National Eye Institute (NEI) More Information Go to Publications: Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 030011 03-EI-0011 First Posted: April 20, 2006 Last Update Posted: July 2, 2017 Last Verified: August 15, 2007 Keywords provided by National Institutes of Health Clinical Center (CC): Eye Movement Niemann Pick C Additional relevant MeSH terms: Layout table for MeSH terms Pick Disease of the Brain Aphasia, Primary (...) Progressive Frontotemporal Dementia Niemann-Pick Diseases Niemann-Pick Disease, Type A Niemann-Pick Disease, Type C Frontotemporal Lobar Degeneration Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Mental Disorders Aphasia Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms TDP-43 Proteinopathies Neurodegenerative Diseases Proteostasis Deficiencies Metabolic Diseases

2006 Clinical Trials

3722. Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

: No Criteria Inclusion Criteria: Diagnosis of Alzheimer's type dementia, rated as severe progressive worsening of memory and other cognitive functions brain imaging (CTor MRI scan) within last 3 years ability to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing. Exclusion Criteria: Dementia caused by cerebrovascular disease disturbances of consciousness, delirium, psychosis severe aphasia or major sensorimotor impairment cognitive impairment due to acute cerebral trauma

2005 Clinical Trials

3723. Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy

and diurnal seizures consisting of simple partial seizures consisting of brief unilateral facial clonic activity, dysphasia, and drooling. The EEG abnormalities are unique, consisting of generally high amplitude, centrotemporal spikes that are activated by sleep. The seizures typically begin in the first decade and almost always stop by age 16 years. The seizures are usually infrequent although clusters of seizures do occur. When the physician elects to treat, the seizures are usually easily controlled

2005 Clinical Trials

3724. Treatment Choices for Improving Adherence and Outcome

ideation aphasia acute or severe medical illness currently receiving either antidepressant medication or psychotherapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00194948 Locations Layout table for location information United States, New York

2005 Clinical Trials

3725. Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial

Martínez. Recruitment status was: Recruiting First Posted : September 20, 2005 Last Update Posted : September 20, 2005 Sponsor: Gabinete Berthier y Martínez Collaborator: H. Lundbeck A/S Information provided by: Gabinete Berthier y Martínez Study Details Study Description Go to Brief Summary: Aphasia, the loss or impairment of language caused by brain damage, is one of the most devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs (...) . Conventional speech-language therapy in chronic aphasic subjects is of little help and several drugs have been studied with limited success. Therefore other therapeutic strategies are warranted. Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may help the recovery of cognitive deficits, included language, in subjects with vascular dementia. The present study examines the safety profile and efficacy of memantine paired with intensive language therapy in subjects with stroke

2005 Clinical Trials

3726. Psychosocial/Behavioral Intervention in Post-Stroke Depression

positive for depressive symptoms by Geriatric Depression Scale Able to provide informed consent - Exclusion Criteria: Subarachnoid or intracranial hemorrhagic stroke Global aphasia Reduced level of consciousness (GCS <15) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier

2005 Clinical Trials

3727. Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome

Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: First ever stroke Any Sleep Apnea symptom Hypertension Exclusion Criteria: Aphasia Cognitive impairment Hypersomnolence Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2005 Clinical Trials

3728. Double Blind Study of Trp01 in Patients With Alzheimer's Disease

according to DSM-IV criteria : development of multiple cognitive deficits manifested by both memory impairment and one or more of the following cognitive disturbances: aphasia, apraxia, agnosia, disturbance in executive functioning the above-mentioned deficits cause significant impairment in social or occupational functioning they do not occur exclusively during the course of delirium Dementia according to communicative disorders and stroke criteria (NINCDS-ADRDA) dementia established clinically

2005 Clinical Trials

3729. Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

: Layout table for MeSH terms Dementia Frontotemporal Dementia Aphasia, Primary Progressive Pick Disease of the Brain Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Mental Disorders Frontotemporal Lobar Degeneration TDP-43 Proteinopathies Neurodegenerative Diseases Proteostasis Deficiencies Metabolic Diseases Aphasia Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms

2005 Clinical Trials

3730. The Effect of Additional Arm Therapy on Arm Function After Stroke

) or neurological conditions (e.g., Parkinson's disease) due to conditions other than stroke, receptive aphasia Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00359255 Locations Layout table for location information Canada, British Columbia Kelowna General

2006 Clinical Trials

3731. The Effect of Aerobic Exercise on Learning After Stroke

to be controlled < month receptive or expressive aphasia as indicated on MMSE multiple strokes or other neuromuscular conditions major depression that is untreated using the Beck depression inventory Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00228306

2005 Clinical Trials

3732. Propofol Injection for Daily Headache

, Those having language barriers (e.g. illiterate, not English-speaking, dysphasic), Known or suspected difficult airway or sleep apnea, Severe respiratory disease, Neuromuscular disease, Seizure disorder, Severe cardiac disease, Severe gastroesophageal reflux disease, Pancreatitis, Lipid disorders, Receiving Total Parenteral Nutrition, Body mass index > 35, diabetes or major endocrine disorder, Hepatic or renal failure, Unstable psychiatric disorder, Known drug abuse, Pregnancy, Cognitively impaired

2005 Clinical Trials

3733. Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

) Stroke was within 30 days of being admitted Medically stable Presence of memory and/or attentional impairments and evidence that these impairments were not present or were less severe prior to the stroke (assessed via interview with family) Approval by individual's attending physician at the rehabilitation hospital Exclusion Criteria: Aphasia or cognitive (or behavioral) impairments severe enough to prevent valid neuropsychiatric assessment Currently experiencing a major depressive episode (unless

2005 Clinical Trials

3734. Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

as defined below: Peripheral lymphocyte count > 20 x 10^9/L Platelet counts ≤ 75,000/µL Hemoglobin level ≤ 9 g/dL Venous pH value out of normal range or oxygen saturation ≤ 90% Known or suspected central nervous system (CNS) involvement by NHL a)History of or current relevant CNS pathology as epilepsy, seizure, paresis,aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis b)Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI

2006 Clinical Trials

3735. mCIMT and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects

part movement in the affected upper extremity and a minimum of 20 degrees of active wrist extension and 10 degrees of finger extension; (4) no severe aphasia that hampers command following; (5) no severe cognitive impairments (Mini-Mental State Examination score >= 22); (6) being right-handed premorbidly by self-report. Exclusion Criteria: Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2005 Clinical Trials

3736. Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with at least a serious, measurable deficit on the NIH Stroke Scale in language (aphasia score > 1), motor power (arm or leg > 1

2005 Clinical Trials

3737. IVPCA in the Management of Pain Following Major Intracranial Surgery

: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Adults undergoing intracranial surgery Exclusion Criteria: Patient refusal Pregnancy Aphasia Respiratory failure Allergy/intolerance to fentanyl Opioids use History of opioid-dependent pain, Patient has been in an investigational drug trial (except chemotherapy) in the month preceding the day of enrollment Mental or physical limitations that would prevent patient assessment or PCA use Chronic painful conditions unrelated to the reason

2006 Clinical Trials

3738. A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

than 1/3 hemisphere Patient having a score below the cut-off point at Frenchay Aphasia Short Test Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276380 Locations Layout table for location information Czechia Faculty of Medicine in Hradec Kralove

2006 Clinical Trials

3739. Vestibular Stimulation to Treat Hemispatial Neglect

of aphasia on clinical examination (crossed aphasia) A significant history of other neurological or psychiatric illness or drug/alcohol abuse Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271388 Locations Layout table for location information United

2005 Clinical Trials

3740. Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Criteria: Patients with known or suspected prior intracranial haemorrhage or history of brain injury or brain tumor. Disorders related to syncope, drop attacks, congenital vascular malformation, aneurysm, angioma, or epilepsy, psychiatric disorders. Peptic ulcer or gastrointestinal bleeding within 6 months. History of hypersensitivity or intolerance to study drugs or aspirin. Experienced habitual headache (any form) within the past 3 months. History of dysphasia, dysphagia, dementia, or unconsciousness

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>